156 related articles for article (PubMed ID: 35934726)
1. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.
Keith PK; Cowan J; Kanani A; Kim H; Lacuesta G; Lee JK; Chen J; Park M; Gladiator A
Allergy Asthma Clin Immunol; 2022 Aug; 18(1):70. PubMed ID: 35934726
[TBL] [Abstract][Full Text] [Related]
2. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
[TBL] [Abstract][Full Text] [Related]
3. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants.
Meckley LM; Wu Y; Tzivelekis S; Gandhi V; Gladiator A
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):568-574.e1. PubMed ID: 34224864
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies - real-world data from the IG TATRY study.
Heropolitańska-Pliszka E; Pac M; Pietrucha B; Machura E; Pukas-Bochenek A; Chrobak E; Bień E; Malanowska M; Pituch-Noworolska A; Drygała S; Kamieniak M; Kasprzak J; Mach-Tomalska M
Expert Rev Clin Immunol; 2023; 19(10):1281-1291. PubMed ID: 37489744
[TBL] [Abstract][Full Text] [Related]
5. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.
Meckley LM; Wu Y; Ito D; Berner T; McCoy B; Yel L
BMC Immunol; 2020 May; 21(1):24. PubMed ID: 32366233
[TBL] [Abstract][Full Text] [Related]
6. Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
Rosenbach K; Park M; Sanchirico M; Nwose O; Paris K
J Clin Immunol; 2023 Jul; 43(5):912-920. PubMed ID: 36809598
[TBL] [Abstract][Full Text] [Related]
7. Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies.
Borte M; Anderson-Smits C; Hermann C
Expert Rev Clin Immunol; 2021 Apr; 17(sup1):7-8. PubMed ID: 33908818
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases.
Gupta S; Stein M; Hussain I; Paris K; Engl W; McCoy B; Rabbat CJ; Yel L
Ann Allergy Asthma Immunol; 2019 Sep; 123(3):271-279.e1. PubMed ID: 31228628
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies.
Paris K; Haddad E; Borte M; Brodszki N; Dérfalvi B; Maródi L; Hussain I; Darter A; Engl W; Leibl H; McCoy B; Yel L
Immunotherapy; 2019 Apr; 11(5):397-406. PubMed ID: 30626238
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
[TBL] [Abstract][Full Text] [Related]
12. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland.
Pollock RF; Meckley LM
Clinicoecon Outcomes Res; 2018; 10():223-229. PubMed ID: 29692618
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes.
Mallick R; Solomon G; Bassett P; Zhang X; Patel P; Lepeshkina O
Allergy Asthma Clin Immunol; 2022 Dec; 18(1):110. PubMed ID: 36566213
[TBL] [Abstract][Full Text] [Related]
15. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.
Suez D; Kriván G; Jolles S; Stein M; Gupta S; Paris K; van Hagen PM; Brodszki N; Engl W; Leibl H; McCoy B; Yel L
Immunotherapy; 2019 Aug; 11(12):1057-1065. PubMed ID: 31268374
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Kanegane H; Endo A; Okada S; Ohnishi H; Ishimura M; Nishikomori R; Imai K; Nonoyama S; Muramatsu H; Wada T; Kuga A; Sakamoto K; Russo-Schwarzbaum S; Chu LH; McCoy B; Li Z; Yel L
Immunother Adv; 2024; 4(1):ltae001. PubMed ID: 38511087
[TBL] [Abstract][Full Text] [Related]
18. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.
Gerth WC; Betschel SD; Zbrozek AS
Allergy Asthma Clin Immunol; 2014; 10(1):23. PubMed ID: 24872821
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
[No Abstract] [Full Text] [Related]
20. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
